Last 12 months
Inside the activity.
0 purchase rows · 57 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 16 |
| Dec 2025 | 0 | 12 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 9 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 1 | $5.43 | $5.43 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 2 | $6.45 | $12.90 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 2 | $10.45 | $20.90 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
GrantCommon Stock | 10,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,055 F1 · kind: Restricted stock units awarded on August 5, 2022 vest 1/3rd on September 2, 2023 and 1/12th per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 00:04 UTC |
Holstein JensDirector
|
GrantCommon Stock | 14,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000088 · wf-form4_165542424124631.xml · nonDerivative · entry 2 Holstein Jens · CIK 0001819880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,731 F2 · kind: Restricted stock units awarded on June 16, 2022 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 00:06 UTC |
JONES EVAN/ FADirector
|
GrantCommon Stock | 14,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000090 · wf-form4_165542436759261.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,451 F1 · kind: Restricted stock units awarded on June 16, 2022 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 00:12 UTC |
EPSTEIN ROBERT SDirector
|
GrantCommon Stock | 14,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000098 · wf-form4_165542475995558.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,451 F1 · kind: Restricted stock units awarded on June 16, 2022 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 00:12 UTC |
EASTHAM KARINDirector
|
GrantCommon Stock | 14,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000097 · wf-form4_165542474197562.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,451 F1 · kind: Restricted stock units awarded on June 16, 2022 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 16, 2022 Filed Jun 16, 2022 20:11 UTC |
BISHOP JOHN LDirector
|
GrantCommon Stock | 14,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000095 · wf-form4_165542470157099.xml · nonDerivative · entry 1 BISHOP JOHN L · CIK 0001189846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,451 F1 · kind: Restricted stock units awarded on June 16, 2022 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 00:12 UTC |
Bhanji MunaDirector
|
GrantCommon Stock | 14,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000096 · wf-form4_165542471995449.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,272 F1 · kind: Restricted stock units awarded on June 16, 2022 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 00:04 UTC |
Holstein JensDirector
|
SaleCommon Stock | 8,720 | $16.27 | $141,846.50 |
DisclosureSEC source: 0001384101-22-000088 · wf-form4_165542424124631.xml · nonDerivative · entry 1 Holstein Jens · CIK 0001819880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $16.25 to $16.32. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 12:19 UTC |
Stapley MarcDirector · Chief Executive Officer
|
PurchaseCommon Stock | 60,000 | $16.33 | $980,094.00 |
DisclosureSEC source: 0001384101-22-000083 · wf-form4_165512274967029.xml · nonDerivative · entry 1 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,761 F1 · price: Represents weighted average purchase price. Purchase prices for the transactions range from $16.24 to $16.40. Detailed information regarding the number of shares purchased at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:45 UTC |
GORDON KEVIN KDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001384101-22-000080 · wf-form4_165489392090834.xml · derivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:45 UTC |
GORDON KEVIN KDirector
|
SaleCommon Stock | 15,000 | $18.50 | $277,501.50 |
DisclosureSEC source: 0001384101-22-000080 · wf-form4_165489392090834.xml · nonDerivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $18.00 to $18.01. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:45 UTC |
GORDON KEVIN KDirector
|
Exercise / conversionCommon Stock | 15,000 | $7.39 | $110,850.00 |
DisclosureSEC source: 0001384101-22-000080 · wf-form4_165489392090834.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 20:24 UTC |
Stapley MarcDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 4,047 | $18.23 | $73,776.81 |
DisclosureSEC source: 0001384101-22-000076 · wf-form4_165454707721517.xml · nonDerivative · entry 1 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,761 F1 · kind: The reporting person is reporting the withholding of 4,047 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 11,701 Restricted Stock Units granted on June 1, 2021 and does not represent a sale by the reporting person. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 20:27 UTC |
Anderson Bonnie HDirector · Executive Chairwoman
|
Tax withholdingCommon Stock | 2,042 | $18.23 | $37,225.66 |
DisclosureSEC source: 0001384101-22-000078 · wf-form4_165454723637529.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,045 F1 · kind: The reporting person is reporting the withholding of 738, 812, and 492 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,875, 2,062 and 1,250 Restricted Stock Units, respectively, granted on February 28, 2019, February 28, 2020 and February 26, 2021 respectively, and does not represent a sale by the reporting person. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 20:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Tax withholdingCommon Stock | 1,008 | $18.23 | $18,375.84 |
DisclosureSEC source: 0001384101-22-000074 · wf-form4_165454691147897.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,353 F1 · kind: The reporting person is reporting the withholding of 248, 372, and 388 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 500, 750 and 781 Restricted Stock Units, respectively, granted on February 28, 2019, February 28, 2020 and February 26, 2021, respectively, and does not represent a sale by the reporting person. Read SEC document |
| May 01, 2022 Filed May 3, 2022 21:43 UTC |
Anderson Bonnie HDirector · Executive Chairwoman
|
Tax withholdingCommon Stock | 736 | $20.47 | $15,065.92 |
DisclosureSEC source: 0001384101-22-000070 · wf-form4_165161419911255.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,952 F1 · kind: The reporting person is reporting the withholding of 736 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,870 Restricted Stock Units granted on May 11, 2020 and does not represent a sale by the reporting person. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 21:34 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,407 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,407 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 21:34 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 100 | $26.49 | $2,649.00 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,391 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 21:34 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 5,844 | $25.70 | $150,189.05 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,491 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.41 to $26.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 21:34 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 17,059 | $24.91 | $424,944.81 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,335 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.40 to $25.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 21:34 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 4,407 | $5.98 | $26,353.86 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| March 04, 2022 Filed Mar 10, 2022 01:46 UTC Amendment |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,407 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,407 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 04, 2022 Filed Mar 10, 2022 01:46 UTC Amendment |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 100 | $26.49 | $2,649.00 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,361 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| March 04, 2022 Filed Mar 10, 2022 01:46 UTC Amendment |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 5,844 | $25.70 | $150,189.05 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,461 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.41 to $26.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2022 Filed Mar 10, 2022 01:46 UTC Amendment |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 17,089 | $24.91 | $425,697.24 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,305 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.40 to $25.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2022 Filed Mar 10, 2022 01:46 UTC Amendment |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 4,407 | $5.98 | $26,353.86 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:46 UTC |
Nova Tina SusanPresident, CLIA U.S.
|
GrantStock Option (right to buy) · Derivative | 103,043 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001384101-22-000052 · wf-form4_164668959681539.xml · derivative · entry 2 Nova Tina Susan · CIK 0001302605 · President, CLIA U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,043 Underlying: Common Stock · 103,043 shares Expires 2032-03-03 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:46 UTC |
Nova Tina SusanPresident, CLIA U.S.
|
GrantCommon Stock | 56,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000052 · wf-form4_164668959681539.xml · nonDerivative · entry 1 Nova Tina Susan · CIK 0001302605 · President, CLIA U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,988 F1 · kind: Restricted stock units awarded on March 3, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:40 UTC |
Chambers RebeccaChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 37,773 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001384101-22-000050 · wf-form4_164668921354091.xml · derivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,773 Underlying: Common Stock · 37,773 shares Expires 2032-03-03 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:40 UTC |
Chambers RebeccaChief Financial Officer
|
GrantCommon Stock | 20,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000050 · wf-form4_164668921354091.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,728 F1 · kind: Restricted stock units awarded on March 3, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:37 UTC |
Stapley MarcDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 103,026 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001384101-22-000048 · wf-form4_164668902627659.xml · derivative · entry 2 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,026 Underlying: Common Stock · 103,026 shares Expires 2032-03-03 F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:37 UTC |
Stapley MarcDirector · Chief Executive Officer
|
GrantCommon Stock | 56,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000048 · wf-form4_164668902627659.xml · nonDerivative · entry 1 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,808 F1 · kind: Restricted stock units awarded on March 3, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. F2 · balance_after: Includes 464 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan on January 31, 2022. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:34 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
GrantStock Option (right to buy) · Derivative | 77,287 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · derivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,287 Underlying: Common Stock · 77,287 shares Expires 2032-03-03 F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:34 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
GrantCommon Stock | 42,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,987 F1 · kind: Restricted stock units awarded on March 3, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:27 UTC |
Anderson Bonnie HDirector · Executive Chairwoman
|
GrantStock Option (right to buy) · Derivative | 32,195 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001384101-22-000044 · wf-form4_164668845403223.xml · derivative · entry 3 Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,195 Underlying: Common Stock · 32,195 shares Expires 2032-03-03 F2 · derivative.exercise_date: The option becomes exercisable as to 33% of the shares on each of the one-year, two-year and three-year anniversaries following grant date, subject to continued service of the Reporting Person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:27 UTC |
Anderson Bonnie HDirector · Executive Chairwoman
|
GrantCommon Stock | 17,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000044 · wf-form4_164668845403223.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,688 F1 · kind: Restricted stock units awarded on March 3, 2022 vest in full on March 2, 2023 subject to continuing service of the Reporting Person. Read SEC document |
| March 03, 2022 Filed Mar 10, 2022 01:46 UTC Amendment |
Kennedy Giulia CChief Scientific & Med Officer
|
GrantStock Option (right to buy) · Derivative | 77,287 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · derivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,287 Underlying: Common Stock · 77,287 shares Expires 2032-03-03 F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2022 Filed Mar 10, 2022 01:46 UTC Amendment |
Kennedy Giulia CChief Scientific & Med Officer
|
GrantCommon Stock | 42,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,987 F1 · kind: Restricted stock units awarded on March 3, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:28 UTC |
Nova Tina SusanPresident, CLIA U.S.
|
Tax withholdingCommon Stock | 10,695 | $27.84 | $297,748.80 |
DisclosureSEC source: 0001384101-22-000038 · wf-form4_164643282257051.xml · nonDerivative · entry 1 Nova Tina Susan · CIK 0001302605 · President, CLIA U.S. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,442 F1 · kind: The reporting person is reporting the withholding of 10,695 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 30,000 Restricted Stock Units granted on March 12, 2021 and does not represent a sale by the reporting person. F2 · balance_after: Includes 1,137 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:35 UTC |
Anderson Bonnie HDirector · Executive Chairwoman
|
Tax withholdingCommon Stock | 4,521 | $27.84 | $125,864.64 |
DisclosureSEC source: 0001384101-22-000042 · wf-form4_164643329059433.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,021 F1 · kind: The reporting person is reporting the withholding of 838, 838, 889, and 1,956 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,875, 1,875, 2,063 and 5,000 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019, February 28, 2020 and February 26, 2021 respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:31 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Tax withholdingCommon Stock | 10,337 | $27.84 | $287,782.08 |
DisclosureSEC source: 0001384101-22-000040 · wf-form4_164643307661177.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,575 F1 · kind: The reporting person is reporting the withholding of 241, 173, 8,582, 260 and 1,081 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 588, 500, 24,000, 750 and 3,125 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019, February 28, 2019, February 28, 2020 and February 26, 2021 respectively, and does not represent a sale by the reporting person. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:05 UTC |
McGuire AnnieSVP, General Counsel
|
GrantStock Option (right to buy) · Derivative | 42,175 | $0.00 Strike: $27.80 | $0.00 |
DisclosureSEC source: 0001384101-22-000034 · wf-form4_164627312110088.xml · derivative · entry 2 McGuire Annie · CIK 0001914620 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,175 Underlying: Common Stock · 42,175 shares Expires 2032-02-28 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:05 UTC |
McGuire AnnieSVP, General Counsel
|
GrantCommon Stock | 22,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000034 · wf-form4_164627312110088.xml · nonDerivative · entry 1 McGuire Annie · CIK 0001914620 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,855 F1 · kind: Restricted stock units awarded on February 28, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:51 UTC |
JONES EVAN/ FADirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000009 · wf-form4_164211068307265.xml · derivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:51 UTC |
JONES EVAN/ FADirector
|
Exercise / conversionCommon Stock | 5,000 | $4.00 | $20,000.00 |
DisclosureSEC source: 0001384101-22-000009 · wf-form4_164211068307265.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:44 UTC |
EASTHAM KARINDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $12.12 | $0.00 |
DisclosureSEC source: 0001384101-21-000184 · wf-form4_164003664535663.xml · derivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,750 Underlying: Common Stock · 5,000 shares Expires 2023-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 17, 2021. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:44 UTC |
EASTHAM KARINDirector
|
SaleCommon Stock | 5,000 | $45.00 | $225,000.00 |
DisclosureSEC source: 0001384101-21-000184 · wf-form4_164003664535663.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 17, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.